Showing 1171-1180 of 4012 results for "".
PROMs: Role in Clinical Research and Contributions to PAH Patient Perspectives
https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.How Do Patient Experiences and PAH Perspectives Vary Across Regions and Cultures Worldwide?
https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.How COVID-19 mRNA Vaccination Restores Sensitivity to Immune Checkpoint Inhibitors
https://reachmd.com/programs/clinicians-roundtable/covid-19-vaccination-immune-checkpoint-inhibitors/48832/A Case Presentation of Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituInnovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
https://reachmd.com/programs/cme/innovative-approaches-to-managing-ckm-syndrome-and-hfmrefhfpef/29912/CKM syndrome and HFmrEF/HFpEF present a rising global burden. Tune in to explore emerging therapies with a proven impact on outcomes.Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
https://reachmd.com/cme/ACC-2025-nsMRA-HF/impact-of-finerenone-on-egfr-slope-by-baseline-albuminuria-in-finearts-hf/35846/Dr. Finnian McCausland shares new data from ERA 2025 showing finerenone slows eGFR decline across albuminuria levels in patients with HFmrEF/HFpEF.Albuminuria Change and Finerenone's Effect on CV Outcomes
https://reachmd.com/cme/ACC-2025-nsMRA-HF/albuminuria-change-and-finerenones-effect-on-cv-outcomes/35847/At ERA 2025, Dr. Finnian McCausland discusses new findings showing that albuminuria reduction with finerenone may predict cardiovascular benefit.Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/Explore the potential of combining a nonsteroidal MRA & SGLT2i in patients with CKD & T2D with expert insights on data from the CONFIDENCE trial.The CONFIDENCE Trial: Data Insights
https://reachmd.com/cme/ERA-2025-nsMRA-CKM/the-confidence-trial-data-insights/35845/Dr. Hiddo Heerspink shares CONFIDENCE trial insights from ERA 2025 showing finerenone + empagliflozin lowers albuminuria in patients with CKD and T2D.Topline Results of the CONFIDENCE Trial
https://reachmd.com/cme/ACC-2025-nsMRA-HF/topline-results-of-the-confidence-trial/35767/Dr. Rajiv Agarwal presents CONFIDENCE topline results: finerenone + empagliflozin lowers albuminuria, showing promise in CKD and T2D care.